Abstract
Primary biliary cirrhosis (PBC) is a chronic and progressive cholestatic liver disease of unknown etiopathogenesis that mainly affects middle-aged women. Patients show non-suppurative cholangitis with damage and destruction of small- and medium-sized intrahepatic bile ducts. Characteristically, the disease is strongly associated with autoimmune phenomena such as the appearance of serum antimitochondrial autoantibodies (AMA) and portal infiltrates with autoreactive T cells which recognize the inner lipoyl domain of the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Here we review the major characteristics of a series of inducible and genetically modified animal models of PBC and analyze their similarities and differences with PBC features in humans.
Keywords: Break of tolerance against PDC-E2, antimitochondrial autoantibodies, autoimmune cholangitis, autoreactive T cells, cytotoxic CD8+ T cells, defective treg cells, cholestasis, AE2 deficiency, deficient bicarbonate secretion.
Current Pharmaceutical Design
Title:Mouse Models of Primary Biliary Cirrhosis
Volume: 21 Issue: 18
Author(s): Axel R. Concepcion and Juan F. Medina
Affiliation:
Keywords: Break of tolerance against PDC-E2, antimitochondrial autoantibodies, autoimmune cholangitis, autoreactive T cells, cytotoxic CD8+ T cells, defective treg cells, cholestasis, AE2 deficiency, deficient bicarbonate secretion.
Abstract: Primary biliary cirrhosis (PBC) is a chronic and progressive cholestatic liver disease of unknown etiopathogenesis that mainly affects middle-aged women. Patients show non-suppurative cholangitis with damage and destruction of small- and medium-sized intrahepatic bile ducts. Characteristically, the disease is strongly associated with autoimmune phenomena such as the appearance of serum antimitochondrial autoantibodies (AMA) and portal infiltrates with autoreactive T cells which recognize the inner lipoyl domain of the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Here we review the major characteristics of a series of inducible and genetically modified animal models of PBC and analyze their similarities and differences with PBC features in humans.
Export Options
About this article
Cite this article as:
Concepcion R. Axel and Medina F. Juan, Mouse Models of Primary Biliary Cirrhosis, Current Pharmaceutical Design 2015; 21 (18) . https://dx.doi.org/10.2174/1381612821666150316121622
DOI https://dx.doi.org/10.2174/1381612821666150316121622 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants
Current Clinical Pharmacology Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research New Pharmaceutical Concepts for Sebaceous Gland Diseases: Implementing Today’s Pre-Clinical Data into Tomorrow’s Daily Clinical Practice
Current Pharmaceutical Biotechnology Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Thrombolytic Therapy in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
Current Gene Therapy Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Identification of Multiple Subcellular Locations for Proteins in Budding Yeast
Current Bioinformatics Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat
Current Diabetes Reviews